The immuno-oncology sector, comprising companies that develop advanced technologies for cancer treatment, has shown promising performance recently. This sector's innovation and critical role in advancing cancer treatments have led to a significant market response, reflected in a notable +8.04% increase in performance over the past week. Below is an analysis of the key players in this group—Corvus Pharmaceuticals (CRVS), AnaptysBio (ANAB), and iTeos Therapeutics (ITOS)—focusing on market capitalization, price movements, volume changes, and technical indicators.
Market Capitalization
The market capitalization of the immuno-oncology group, on average, stands at $563.3 million. This figure highlights the relatively moderate size of the companies within this specialized sector. Among these companies, AnaptysBio (ANAB) leads with a market cap of $924.2 million, signifying its strong position and valuation in the market. On the other hand, Corvus Pharmaceuticals (CRVS) has the smallest market cap at $224.6 million, suggesting a more speculative and potentially high-risk profile.
Price Movements: Highs and Lows
The price movements within this group have been particularly dynamic. Over the past week, the average price growth across all the stocks was 1.47%. However, the monthly price growth was significantly higher, averaging 42.58%, and the quarterly price growth was 49.25%. These figures indicate a sector that is experiencing rapid price fluctuations, which could be driven by clinical trial results, regulatory approvals, or market speculation.
Corvus Pharmaceuticals (CRVS): CRVS has been the standout performer in terms of price appreciation, with a weekly growth of +20.07%. This robust increase positions CRVS as a top gainer in the penny stock category, rising +17.34% in just one week. However, it's worth noting that earlier this year, CRVS also experienced significant volatility, with a notable -17.11% decline in mid-March.
AnaptysBio (ANAB): ANAB had a remarkable +26.9% price jump in early May, which has contributed to its strong performance over the quarter. However, recent indicators suggest a potential reversal, as the RSI oscillator has moved out of the overbought zone, which could indicate a downturn.
iTeos Therapeutics (ITOS): ITOS has faced some challenges, with the stock seeing a -14.23% decline, making it the biggest loser in the group. Despite this, the Aroon Indicator suggests a bullish signal, indicating that ITOS may be poised for a rebound.
Volume Trends
Volume trends across the immuno-oncology group have been notably high, reflecting strong investor interest and market activity.
iTeos Therapeutics (ITOS): ITOS saw an extraordinary increase in trading volume, with a one-day spike of 298% above the 65-Day Volume Moving Average. This surge could be an indication of increased investor interest or significant market events that prompted more active trading.
Corvus Pharmaceuticals (CRVS): CRVS experienced a sustained increase in trading volume, with five consecutive days of rising volume, averaging a daily gain of 211%. This sustained increase suggests ongoing investor attention and possibly institutional buying.
AnaptysBio (ANAB): ANAB also saw a significant volume increase, with a record-breaking one-day growth of 320% above the 65-Day Volume Moving Average. This sharp rise could indicate heightened interest or market-moving news that attracted traders to the stock.
CRVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 41 cases where CRVS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The RSI Indicator entered the oversold zone -- be on the watch for CRVS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRVS advanced for three days, in of 240 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 128 cases where CRVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Momentum Indicator moved below the 0 level on December 03, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on CRVS as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CRVS turned negative on November 12, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
CRVS moved below its 50-day moving average on December 13, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CRVS crossed bearishly below the 50-day moving average on December 16, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (38.314) is normal, around the industry mean (14.626). P/E Ratio (0.000) is within average values for comparable stocks, (87.424). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.836). CRVS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (260.938).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in the development of biopharmaceuticals therapeutic products and services
Industry Biotechnology